1Yen MS, Twu NF, Lai CR, et al. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer[J]. Gynecol Oncol , 2009,114 (3): 415419.
2Alberts OS, Liu PY ,Hannigan EV, et al. Intraperitoneal cispla?tin plus intravenous cyclophosphamide versus intravenous cispla?tin plus intravenous cyclophosphamide for stage III ovarian canc?err]]. N EnglJ Med, 1996,335 (26): 1950-1955.
3Armstrong OK, Bundy B , Wenzel L, et al. Intraperitoneal cispla?tin and paclitaxel in ovarian cancer[J]. N EnglJ Med, 2006, 354 (I) : 3443.
4Kirmani S, Braly PS, McClay EF, et al. A comparison of intrave?nous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer[J]. Gynecol Oncol, 1994, 54 (3): 338- 344.
5Polyzos A, Tsavaris N ,Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with in?travenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer[J]. Oncology, 1999, 56 (4) : 291- 296.
6Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophos?phamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Onco?logico Nord-Ovest[J]. Gynecol Oncol, 2000, 76 (2): 157- 162.
7Markman M, Bundy BN, Alberts OS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moder?ately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carci?noma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncolo?gy Group[J].J Clin Oncol, 2001, 19 (4) : 1001-1007.
8Yen MS, luang CM, Lai CR, et al. Intraperitoneal cisplatin?based chemotherapy vs. intravenous cisplatin-based chemothera?py for stage III optimally cytoreduced epithelial ovarian cancer[J]. IntJ Gynaecol Obstet, 2001, 72 (1) : 55-60.
9Markman M. Intraperitoneal antineoplastic drug delivery: ration?ale and results[J]. Lancet Oncol , 2003, 4 (5) : 277 -283.
10Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cis?platin therapy in ovarian cancer: comparison with standard in?travenous carboplatin and paclitaxel[1J. Gynecol Oneol, 2006, 103 (1) : 1-6.
